Synthesis of artemiside and its effects in combination with conventional drugs against severe murine malaria

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 163-173

  Guo, Jin ^a   Guiguemde, Armand W ^b   Bentura Marciano, Annael ^c   Clark, Julie ^b   Haynes, Richard K ^d   Chan, Wing Chi ^d   Wong, Ho Ning ^d   Hunt, Nicholas H ^a   Guy, R Kiplin ^b   Golenser, Jacob ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISIDE; ARTEMISONE; ARTESUNATE; CHLOROQUINE; DIHYDROARTEMISININ; MEFLOQUINE; PIPERAQUINE; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; BRAIN MALARIA; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MALARIA; MONOTHERAPY; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MALARIA, CEREBRAL; MALARIA, FALCIPARUM; MEFLOQUINE; MICE; MICE, INBRED C57BL; MICROSCOPY; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; QUINOLINES; RECURRENCE; SURVIVAL RATE;

EID: 84455170032     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05006-11     Document Type: Article

References (49)

1. Adjuik M, et al. 2002. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 359:1365-1372. (Pubitemid 34442375)
2. Ashley EA, White NJ. 2005. Artemisinin-based combinations. Curr. Opin. Infect. Dis. 18:531-536. (Pubitemid 41634767)
3. Bliss CI. 1939. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26:585-615.
4. Buffet PA, et al. 2011. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 117:381-392.
5. Canfield CJ, Pudney M, Gutteridge WE. 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp. Parasitol. 80:373-381.
6. Carter JA, Neville BGR, Newton C. 2003. Neuro-cognitive impairment following acquired central nervous system infections in childhood: a systematic review. Brain Res. Rev. 43:57-69. (Pubitemid 37130080)
7. Chanling T, Neill AL, Hunt NH. 1992. Early microvascular changes in murine cerebral malaria detected in retinal wholemounts. Am. J. Pathol. 140:1121-1130.
8. Codd A, Teuscher F, Kyle DE, Cheng Q, Gatton ML. 2011. Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malar. J. 10:56.
9. D'Alessandro S, et al. 2007. Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone: Implications for embryotoxicity. Toxicology 241:66-74. (Pubitemid 47599780)
10. Ding XC, Beck HP, Raso G. 2011. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol. 27:73-81.
11. Dondorp AM, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
12. Dunay IR, Chan WC, Haynes RK, Sibley LD. 2009. Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model. Antimicrob. Agents Chemother. 53:4450-4456.
13. Eastman RT, Fidock DA. 2009. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7:864-874.
14. Engwerda C, Belnoue E, Gruner AC, Renia L. 2005. Experimental models of cerebral malaria, p. 103-143. In Langhorne J (ed), Immunology and immunopathogenesis of malaria, vol. 297. Springer-Verlag, Berlin, Germany.
15. Fogli S, et al. 2010. Therapeutic potential of sulindac hydroxamic acid against human pancreatic and colonic cancer cells. Eur. J. Med. Chem. 45:5100-5107.
16. Golenser J, McQuillan J, Hee L, Mitchell AJ, Hunt NH. 2006. Conventional and experimental treatment of cerebral malaria. Int. J. Parasitol. 36:583-593. (Pubitemid 43674518)
17. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. 2006. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. 36:1427-1441. (Pubitemid 44751746)
18. Hastings I. 2011. How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Trends Parasitol. 27:67-72.
19. Haynes RK, et al. 2010. Facile oxidation of leucomethylene blue and dihydroflavins by artemisinins: relationship with flavoenzyme function and antimalarial mechanism of action. ChemMedChem 5:1282-1299.
20. Haynes RK, et al. 2011. Reactions of antimalarial peroxides with each of leucomethylene blue and dihydroflavins: flavin reductase and the cofactor model exemplified. ChemMedChem 6:279-291.
21. Haynes RK, et al. 2006. Artemisone-a highly active antimalarial drug of the artemisinin class. Angew. Chem. Int. Ed. Engl. 45:2082-2088. (Pubitemid 44105182)
22. Ho M, et al. 1998. Endogenous interleukin-10 modulates proinflammatory response in Plasmodium falciparum malaria. J. Infect. Dis. 178:520-525. (Pubitemid 28347937)
23. Hunt NH, et al. 2006. Immunopathogenesis of cerebral malaria. Int. J. Parasitol. 36:569-582. (Pubitemid 43674512)
24. Idro R, Jenkins NE, Newton C. 2005. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 4:827-840. (Pubitemid 41619438)
25. Idro R, et al. 2010. Severe neurological sequelae and behaviour problems after cerebral malaria in Ugandan children. BMC Res. Notes 3:104.
26. Idro R, Marsh K, John CC, Newton CRJ. 2010. Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr. Res. 68:267-274.
27. Jiang JB, Guo XB, Li GQ, Kong YC, Arnold K. 1982. Antimalarial activity of mefloquine and qinghaosu. Lancet ii:285-288. (Pubitemid 12089611)
28. John CC, et al. 2008. Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics 122:E92-E99.
29. Kaewpongsri S, et al. 2011. The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum. Antimicrob. Agents Chemother. 55:1300-1304.
30. Kossodo S, et al. 1997. Interleukin-10 modulates susceptibility in experimental cerebral malaria. Immunology 91:536-540. (Pubitemid 27312334)
31. Lin JT, Juliano JJ, Wongsrichanalai C. 2010. Drug-resistant malaria: the era of ACT. Curr. Infect. Dis. Rep. 12:165-173.
32. Maitland K, Newton C. 2005. Acidosis of severe falciparum malaria: heading for a shock? Trends Parasitol. 21:11-16. (Pubitemid 40082093)
33. Mutabingwa TK. 2005. Artemisinin-based combination therapies (ACTS): best hope for malaria treatment but inaccessible to the needy! Acta Trop. 95:305-315. (Pubitemid 41207297)
34. Nagelschmitz J, et al. 2008. First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob. Agents Chemother. 52:3085-3091.
35. Neill AL, Hunt NH. 1992. Pathology of fatal and resolving Plasmodium berghei cerebral malaria in mice. Parasitology 105:165-175.
36. Nosten F, White NJ. 2007. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77:181-192.
37. Obaldia N, et al. 2009. Evaluation of artemisone combinations in aotus monkeys infected with Plasmodium falciparum. Antimicrob. Agents Chemother. 53:3592-3594.
38. O'Neill PM, Barton VE, Ward SA. 2010. The molecular mechanism of action of artemisinin-the debate continues. Molecules 15:1705-1721.
39. Reddy GM, Mukkanti K, Bhaskar BV, Reddy PP. 2009. Synthesis of metabolites and related substances of rabeprazole, an anti-ulcerative drug. Synth. Commun. 39:278-290.
40. Reis PA, et al. 2010. Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy. PLoS Pathog. 6:e1000963.
41. Serghides L, et al. 2009. Rosiglitazone modulates the innate immune response to plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J. Infect. Dis. 199:1536-1545.
42. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. 2004. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob. Agents Chemother. 48:1803-1806. (Pubitemid 38544392)
43. Smithuis F, et al. 2010. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect. Dis. 10:673-681.
44. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
45. van Hensbroek MB, Palmer A, Jaffar S, Schneider G, Kwiatkowski D. 1997. Residual neurologic sequelae after childhood cerebral malaria. J. Pediatr. 131:125-129. (Pubitemid 27498320)
46. Waknine-Grinberg JH, et al. 2010. Artemisone effective against murine cerebral malaria. Malar. J. 9:227.
47. WHO. 2011. Global plan for artemisinin resistance containment. WHO, Geneva, Switzerland.
48. WHO.2010. Guidelines for the treatment of malaria.WHO,Geneva, Switzerland.
49. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. 2004. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am. J. Trop. Med. Hyg. 71:179-186. (Pubitemid 39121321)